1887

Microbiology Society logo

Volume 162, Issue 8

Laterosporulin10: a novel defensin like Class IId bacteriocin from sp. strain SKDU10 with inhibitory activity against microbial pathogens Free

Abstract

Bacteriocins are antimicrobial peptides (AMPs) produced by bacteria to acquire survival benefits during competitive inter- and intra-species interactions in complex ecosystems. In this study, an AMP-producing soil bacterial strain designated SKDU10 was isolated and identified as a member of the genus . The AMP produced by strain SKDU10 identified as a class IId bacteriocin with 57.6 % homology to laterosporulin, a defensin-like class IId bacteriocin. However, substantial differences were observed in the antimicrobial activity spectrum of this bacteriocin named laterosporulin10 when compared to laterosporulin. Laterosporulin10 effectively inhibited the growth of and (Mtb H37Rv) with LD values of 4.0 µM and 0.5 µM, respectively. Furthermore, laterosporulin10 inhibited the growth of Mtb H37Rv strain at about 20 times lower MIC value compared to MTCC 1430 or MC2 155 and . Electron micrographs along with membrane permeabilization studies using FACS analysis revealed that laterosporulin10 is a membrane-permeabilizing peptide. Interestingly, laterosporulin10 was able to efficiently kill Mtb H37Rv strain residing inside the macrophages and did not show haemolysis up to 40 µM concentration.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Bacteriocin , M. tuberculosis , MALDI , S. aureus , Brevibacillus and Laterosporulin10
© 2016 The Authors
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.000316
2016-08-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/micro/162/8/1286.html?itemId=/content/journal/micro/10.1099/mic.0.000316&mimeType=html&fmt=ahah

References

  1. Arndt-Jovin D. J., Jovin T. M. 1989; Fluorescence labeling and microscopy of DNA. Methods Cell Biol 30:417–448[PubMed] [CrossRef]
     [Google Scholar]
  2. Arnison P. G., Bibb M. J., Bierbaum G., Bowers A. A., Bugni T. S., Bulaj G., Camarero J. A., Campopiano D. J., Challis G. L. et al. 2013; Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 30:108–160 [View Article][PubMed]
     [Google Scholar]
  3. Aziz R. K., Bartels D., Best A. A., DeJongh M., Disz T., Edwards R. A., Formsma K., Gerdes S., Glass E. M. et al. 2008; The RAST Server: rapid annotations using subsystems technology. BMC Genomics 9:75 [View Article][PubMed]
     [Google Scholar]
  4. Baindara P., Mandal S. M., Chawla N., Singh P. K., Pinnaka A. K., Korpole S. 2013; Characterization of two antimicrobial peptides produced by a halotolerant Bacillus subtilis strain SK.DU.4 isolated from a rhizosphere soil sample. AMB Express 3:2 [View Article][PubMed]
     [Google Scholar]
  5. Baindara P., Chaudhry V., Mittal G., Liao L. M., Matos C. O., Khatri N., Franco O. L., Patil P. B., Korpole S. 2016; Characterization of the antimicrobial peptide penisin, a class Ia novel lantibiotic from Paenibacillus sp. Strain A3. Antimicrob Agents Chemother 60:580–591 [View Article]
     [Google Scholar]
  6. Carrillo C., Teruel J. A., Aranda F. J., Ortiz A. 2003; Molecular mechanism of membrane permeabilization by the peptide antibiotic surfactin. Biochim Biophys Acta 1611:91–97 [CrossRef]
     [Google Scholar]
  7. Carroll J., Field D., O' Connor P. M., Cotter P. D., Coffey A., Hill C., O’ Mahony J., Ross R. P. 2010a; Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng Bugs 1:408–412 [View Article]
     [Google Scholar]
  8. Carroll J., Draper L. A., O’Connor P. M., Coffey A., Hill C., Ross R. P., Cotter P. D., O’Mahony J. 2010b; Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 36:132–136 [View Article]
     [Google Scholar]
  9. Chaturvedi V., Ramani R., Andes D., Diekema D. J., Pfaller M. A., Ghannoum M. A., Knapp C., Lockhart S. R., Ostrosky-Zeichner L. et al. 2011; Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis . Antimicrob Agents Chemother 55:1543–1548 [View Article]
     [Google Scholar]
  10. Cotter P. D., Ross R. P., Hill C. 2013; Bacteriocins – a viable alternative to antibiotics?. Nat Rev Microbiol 11:95–105 [View Article][PubMed]
     [Google Scholar]
  11. Desjardine K., Pereira A., Wright H., Matainaho T., Kelly M., Andersen R. J. 2007; Tauramamide, a lipopeptide antibiotic produced in culture by Brevibacillus laterosporus isolated from a marine habitat: structure elucidation and synthesis. J Nat Prod 70:1850–1853 [View Article][PubMed]
     [Google Scholar]
  12. Donaghy J. 2010; Lantibiotics as prospective antimycobacterial agents. Bioeng Bugs 1:437–439 [View Article][PubMed]
     [Google Scholar]
  13. Fickers P. 2013; Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1. PLoS One 8:e83037 [View Article][PubMed]
     [Google Scholar]
  14. Fresard I., Bridevaux P. O., Rochat T., Janssens J. P. 2011; Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly 141:w13240 [View Article][PubMed]
     [Google Scholar]
  15. Grosset J., Leventis S. 1983; Adverse effects of rifampin. Rev Infect Dis 5:S440–450 [View Article][PubMed]
     [Google Scholar]
  16. Gutsmann T. 2016; Interaction between antimicrobial peptides and mycobacteria. Biochim Biophys Acta 1858:1034–1043 [View Article][PubMed]
     [Google Scholar]
  17. Hartmann M., Berditsch M., Hawecker J., Ardakani M. F., Gerthsen D., Ulrich A. S. 2010; Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy. Antimicrob Agents Chemother 54:3132–3142 [View Article][PubMed]
     [Google Scholar]
  18. Kamiyama T., Umino T., Nakamura Y., Itezono Y., Sawairi S., Satoh T., Yokose K. 1994; Bacithrocins A, B and C, novel thrombin inhibitors. J Antibiot 47:959–968 [View Article][PubMed]
     [Google Scholar]
  19. Kaplan C. W., Sim J. H., Shah K. R., Kolesnikova-Kaplan A., Shi W., Eckert R. 2011; Selective membrane disruption: mode of action of C16G2, a specifically targeted antimicrobial peptide. Antimicrob Agents Chemother 55:3446–3452 [View Article][PubMed]
     [Google Scholar]
  20. Klaenhammer T. R. 1993; Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 12:39–85 [CrossRef]
     [Google Scholar]
  21. Kumar A., Deshane J. S., Crossman D. K., Bolisetty S., Yan B. S., Kramnik I., Agarwal A., Steyn A. J. 2008; Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 283:18032–18039 [View Article][PubMed]
     [Google Scholar]
  22. Lee Y.-S., Lee D.-Y., Kim Y. B., Lee S.-W., Cha S.-W., Park H.-W., Kim G.-S., Kwon D.-Y., Lee M.-H. et al. 2015; The mechanism underlying the antibacterial activity of shikonin against methicillin-resistant Staphylococcus aureus . Evidence-Based Complement Altern Med 2015:1–9 [View Article]
     [Google Scholar]
  23. Ma S., Zhao Y., Xia X., Dong X., Ge W., Li H. 2015; Effects of Streptococcus sanguinis Bacteriocin on cell surface hydrophobicity, membrane permeability, and ultrastructure of Candida Thallus . Biomed Res Int1–8
     [Google Scholar]
  24. Maftah A., Renault D., Vignoles C., Héchard Y., Bressollier P., Ratinaud M. H., Cenatiempo Y., Julien R. 1993; Membrane permeabilization of Listeria monocytogenes and mitochondria by the bacteriocin mesentericin Y105. J Bacteriol 175:3232–3235[PubMed]
     [Google Scholar]
  25. Mandal S. M., Dey S., Mandal M., Sarkar S., Maria-Neto S., Franco O. L. 2009; Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. Peptides 30:633–637 [View Article][PubMed]
     [Google Scholar]
  26. Martínez B., Böttiger T., Schneider T., Rodríguez A., Sahl H.-G., Wiedemann I. 2008; Specific interaction of the unmodified bacteriocin Lactococcin 972 with the cell wall precursor lipid II. Appl Environ Microbiol 74:4666–4670 [View Article]
     [Google Scholar]
  27. Nakatsuji T., Gallo R. L. 2014; Dermatological therapy by topical application of non-pathogenic bacteria. J Invest Dermato 134:11–14 [View Article]
     [Google Scholar]
  28. Nilsen T., Nes I. F., Holo H. 2003; Enterolysin A, a cell wall-degrading bacteriocin from Enterococcus faecalis LMG 2333. Appl Environ Microbiol 69:2975–2984 [View Article][PubMed]
     [Google Scholar]
  29. Oliveira E. J. D., Rabinovitch L., Monnerat R. G., Konovaloff L., Passos J., Zahner V., Icrobiol A. P. P. L. E. N. M. 2004; Molecular characterization of Brevibacillus laterosporus and its potential use in biological control. 706657–6664
  30. Pettit R. K., Weber C. A., Kean M. J., Hoffmann H., Pettit G. R., Tan R., Franks K. S., Horton M. L. 2005; Microplate Alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother 49:2612–2617 [View Article][PubMed]
     [Google Scholar]
  31. Piper C., Casey P. G., Hill C., Cotter P. D., Ross R. P. 2012; The lantibiotic Lacticin 3147 prevents systemic spread of Staphylococcus aureus in a murine infection model. Int J Microbiol 2012: [View Article][PubMed]
     [Google Scholar]
  32. Raje M., Dhiman R., Majumdar S., Dass T., Dikshit K. L., Kaur R. 2006; Charged nylon membrane substrate for convenient and versatile high resolution microscopic analysis of Escherichia coli & mammalian cells in suspension culture. Cytotechnology 51:111–117 [View Article][PubMed]
     [Google Scholar]
  33. Ramón-García S., Mikut R., Ng C., Ruden S., Volkmer R., Reischl M., Hilpert K., Thompson C. J. 2013; Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 57:2295–2303 [View Article][PubMed]
     [Google Scholar]
  34. Ruiu L., Satta A., Floris I. 2014; Administration of Brevibacillus laterosporus spores as a poultry feed additive to inhibit house fly development in feces: a new eco-sustainable concept. Poult Sci 93:519–526 [View Article][PubMed]
     [Google Scholar]
  35. Semvua H. H., Kibiki G. S., Kisanga E. R., Boeree M. J., Burger D. M., Aarnoutse R. 2015; Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit 37:22–32 [CrossRef]
     [Google Scholar]
  36. Sharma V., Singh P. K., Midha S., Ranjan M., Korpole S., Patil P. B. 2012; Genome sequence of Brevibacillus laterosporus strain GI-9. J Bacteriol 194:1279 [View Article][PubMed]
     [Google Scholar]
  37. Shida O., Takagi H., Kadowaki K., Komagata K. 1996; Proposal for two new genera, Brevibacillus gen. nov. and Aneurinibacillus gen. nov. Int J Syst Bacteriol 46:939–946 [View Article][PubMed]
     [Google Scholar]
  38. Singh P. K., Chittpurna, Ashish, Sharma V., Patil P. B., Korpole S. 2012; Identification, purification and characterization of laterosporulin, a novel bacteriocin produced by Brevibacillus sp. strain GI-9. PLoS One 7:e31498 [View Article][PubMed]
     [Google Scholar]
  39. Singh P. K., Solanki V., Sharma S., Thakur K. G., Krishnan B., Korpole S. 2014; The intramolecular disulfide-stapled structure of laterosporulin, a class IId bacteriocin, conceals a human defensin-like structural module. FEBS J1–12
     [Google Scholar]
  40. Smirnova T. A., Minenkova I. B., Orlova M. V., Lecadet M. M., Azizbekyan R. R. 1996; The crystal-forming strains of Bacillus laterosporus . Res Microbiol 147:343–350 [View Article][PubMed]
     [Google Scholar]
  41. Smolarczyk R., Cichoń T., Kamysz W., Głowala-Kosińska M., Szydło A., Szultka L., Sieroń A. L., Szala S. 2010; Anticancer effects of CAMEL peptide. Lab Invest 90:940–952 [View Article][PubMed]
     [Google Scholar]
  42. Sosunov V., Mischenko V., Eruslanov B., Svetoch E., Shakina Y., Stern N., Majorov K., Sorokoumova G., Selishcheva A. et al. 2007; Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother 59:919–925 [View Article][PubMed]
     [Google Scholar]
  43. Stern N. J., Svetoch E. A., Eruslanov B. V., Perelygin V. V., Mitsevich E. V., Mitsevich I. P., Pokhilenko V. D., Levchuk V. P., Svetoch O. E. et al. 2006; Isolation of a Lactobacillus salivarius strain and purification of its bacteriocin, which is inhibitory to Campylobacter jejuni in the chicken gastrointestinal system. AAC 50:3111–3116 [View Article]
     [Google Scholar]
  44. Teixeira M. L., Rosa A. D., Brandelli A. 2013; Characterization of an antimicrobial peptide produced by Bacillus subtilis subsp. spizezinii showing inhibitory activity towards Haemophilus parasuis. Microbiology 159:980–988 [View Article]
     [Google Scholar]
  45. Theodore C. M., Stamps B. W., King J. B., Price L. S. L., Powell D. R., Stevenson B. S., Cichewicz R. H. 2014; Genomic and metabolomic insights into the natural product biosynthetic diversity of a feral-hog-associated Brevibacillus laterosporus strain. PLoS One 9:3–12 [View Article]
     [Google Scholar]
  46. Umezawa K., Takeuchi T. 1987; Spergualin: a new antitumour antibiotic. Biomed Pharmacother 41:227–232[PubMed]
     [Google Scholar]
  47. van Belkum M. J., Kok J., Venema G., Holo H., Nes I. F., Konings W. N., Abee T. 1991; The bacteriocin lactococcin A specifically increases permeability of lactococcal cytoplasmic membranes in a voltage-independent, protein-mediated manner. J Bacteriol 173:7934–7941[PubMed]
     [Google Scholar]
  48. van Belkum M. J., Martin-Visscher L. A., Vederas J. C. 2011; Structure and genetics of circular bacteriocins. Trends Microbiol 19:411–418 [View Article][PubMed]
     [Google Scholar]
  49. Yew W. W., Leung C. C., Leung C. C. 2006; Antituberculosis drugs and hepatotoxicity . Respirology 11:699–707 [View Article][PubMed]
     [Google Scholar]
  50. Yoneyama F., Imura Y., Ohno K., Zendo T., Nakayama J., Matsuzaki K., Sonomoto K. 2009; Peptide-lipid huge toroidal pore, a new antimicrobial mechanism mediated by a Lactococcal Bacteriocin, Lacticin Q. Antimicrob Agents Chemother 53:3211–3217 [View Article]
     [Google Scholar]
  51. Yoneyama F., Ohno K., Imura Y., Li M., Zendo T., Nakayama J., Matsuzaki K., Sonomoto K. 2011; Lacticin Q-mediated selective toxicity depending on physicochemical features of membrane components. Antimicrob Agents Chemother 55:2446–2450 [View Article][PubMed]
     [Google Scholar]
  52. Zhao J., Guo L., Zeng H., Yang X., Yuan J., Shi H., Xiong Y., Chen M., Han L. et al. 2012; Purification and characterization of a novel antimicrobial peptide from Brevibacillus laterosporus strain A60. Peptides 33:206–211 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.000316
Loading
Laterosporulin10: a novel defensin like Class IId bacteriocin from Brevibacillus sp. strain SKDU10 with inhibitory activity against microbial pathogens
Microbiology 162, 1286 (2016); https://doi.org/10.1099/mic.0.000316
/content/journal/micro/10.1099/mic.0.000316
/content/journal/micro/10.1099/mic.0.000316
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error